Abstract
The anti-HPV vaccine is the second vaccine for the prevention of some types of cancer, made on the basis of VLP (virus-like particle) technology. Since its appearance, it has proven effectiveness in conditions of excellent safety. This review aims at clarifying some important aspects, based on the evidence accumulated in recent years, such as the vaccines available, the number of doses, and the vaccination of particular categories – immunocompromised patients, vaccination after LEEP excisions, or vaccination in old patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
